<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710214</url>
  </required_header>
  <id_info>
    <org_study_id>P0512236</org_study_id>
    <nct_id>NCT02710214</nct_id>
  </id_info>
  <brief_title>A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis</brief_title>
  <acronym>MS-TSEC</acronym>
  <official_title>Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal
      symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo
      controlled pilot study, is to determine whether this medication alleviates menopausal
      symptoms in women with MS. The investigators will secondarily determine whether addressing
      menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening
      inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Menopause in MS. Multiple sclerosis (MS) affects 3 times more women than men, and before age
      50 in about 90% cases, i.e. prior to menopause. There is broad evidence for hormonal
      regulation of MS in animal models and in clinical cohorts. Around menopause, many clinical
      patients report symptom worsening associated with hot flashes, sleep disturbance or mood
      changes. Additionally, individuals at MS may be at increased risk of developing osteoporosis.
      Longer-term, an age-related decline in gonadal steroids might represent one sex-specific
      influence on the known age-related increases in disability and conversion to progressive
      course, which is marked by accelerated brain volume loss and neurodegeneration. Recent data
      suggest that MS disease severity may worsen after menopause.

        -  Hormone therapy (HT). Despite the benefits of HT (menopausal symptoms, bone density),
           very few women (&lt;30% of our cohort) are currently taking HT for menopausal symptoms;
           this is a result of risks such as (1) breast and endometrial cancer, and (2) stroke in
           older women in the Women's Health Initiative. Recent data on HT use in MS (Nurses Health
           Study) did not show any adverse effects on MS course, and women who used HT reported
           better physical function than women who did not (Bove et al, Neurology 2016).

        -  Study Drug: Duavee, a tissue selective estrogen complex (TSEC), combines conjugated
           estrogens (CE) with the selective estrogen receptor modulator (SERM) bazedoxifene (BZA).
           BZA offsets estrogenic stimulation of endometrial and breast tissue, and CE 0.45mg/BZA
           20mg is approved for menopausal symptom (hot flash) relief and osteoporosis prevention,
           with a favorable tolerability and safety profile.

      In the current study, 24 women with MS and who are experiencing bothersome menopause symptoms
      will be enrolled and randomized to receive either 8 weeks of Duavee or 8 weeks of placebo.
      Visits will be: eligibility, baseline, and 2 month visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot Flash Related Daily Interference Scale (HFRDIS) Score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The interference of vasomotor symptoms (VMS) with daily life will be assessed using the HFRDIS. Scores range from 0 to 100; higher scores indicate greater interference of hot flashes with daily life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The number of women experiencing reduction in hot flashes at week 8 compared to baseline will be counted; when baseline data is unavailable 1-2 week on study data will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Average Hot Flashes Per Day From Baseline to 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The average reduction in hot flashes per day over the course of the trial will be determined from the difference between 8 week and baseline frequency (by randomization group, treatment or placebo). When baseline data is not available, the 2 weeks on study data will be used as 'baseline'. Differences &lt;0 indicate reduction in hot flash frequency over the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Side Effects on the Treatment Satisfaction Questionnaire for Medication (TSQM)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary measure will be the percentage of subjects reporting side effects (yes or no) on the Satisfaction Questionnaire for Medication (TSQM). The TSQM is used to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>EDSS total score is a metric used for quantifying disability in MS and monitoring changes in the level of disability over time. The EDSS will be assessed by a the trial neurologist at baseline and end of study (8 weeks). The score range is 0 to 10; higher scores indicate greater disability. All analyses were performed according to the intention-to-treat principle (primary) then the per-protocol principle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the MS Quality of Life 54 (MSQOL-54)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>MS Quality of Life 54 (MSQOL-54) composite scores provide a patient reported quality of life score assessing physical QOL and mental QOL. A sub-scale of this assessment also assesses energy QOL. These will be measured at baseline and end of study (8 weeks). These scores fall within the range of 0 to 100; higher scores indicate better QOL within that domain or sub-scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Bladder Control Scale (BLCS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Bladder function will be assessed using the BLCS. Patient reported scores will be collected at baseline and at the end of study (8 weeks); scores fall within the range of 0 to 12. Higher scores indicate worse bladder function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Multiple Sclerosis Rating Scale (MSRS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Patient reported disability will be measured by the MSRS at baseline and end of study (8 weeks). Scores range of 0 to 32; higher scores indicate worse patient reported disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Cognitive function will be assessed by the MSNQ at baseline and end of study (8 weeks). Scores range 0 to 60 (scores &gt;27 indicate cognitive impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Symbol Digit Modalities Test (SDMT) Raw Score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>SDMT is a screening instrument commonly used in clinical and research settings to assess cognitive dysfunction in MS. The SDMT will be administered at baseline and end of study (8 weeks). The final raw score is the correct number responses completed in 90 seconds and scores range between 0 and 110; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SDMT Z-score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Regression-based norms for the SDMT were used to convert participants' raw scores at baseline and end of study (8 weeks) to demographically adjusted Z-scores, correcting for the effects of age, gender, and education. Scores are normalized so that 0 represents the mean, scores above 0 fall above the mean and are associated with greater performance on the SDMT. Scores below 0 fall below the mean and are associated with poorer performance on the SDMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Letter Number Sequencing (LNS) Performance</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The LNS is administered to asses working memory and processing speed at baseline and end of study (8 weeks). The score range is 0 to 21; higher scores indicate better performance on this test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New or Enhancing Lesions on MRI</measure>
    <time_frame>8 weeks</time_frame>
    <description>To verify that CE+BZA does not yield any marked changes in inflammatory activity, a randomized subset of 12 participants will undergo MRI at baseline and end of study (8 weeks) to evaluate for new T2 lesions and new gadolinium enhancing lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Missed Doses</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of missed doses will be assed at the end of study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Menopause</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Duavee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Selective Estrogen Complex</intervention_name>
    <description>Once-daily dosing of Duavee for 8 weeks.</description>
    <arm_group_label>Duavee</arm_group_label>
    <other_name>Duavee</other_name>
    <other_name>TSEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once-daily dosing of placebo for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 40-62 years.

          -  Perimenopausal: 6 months of amenorrhea; women who had a bi-lateral oophorectomy; women
             without a uterus and who still have one or both ovaries, with FSH level &gt; 20 mIU/mL
             and estradiol ≤ 50 pg/mL; women with a uterus who have skipped 2 or more menstrual
             cycles with an amenorrhea interval; women who are using the Mirena IUD or who have had
             an endometrial ablation and who still have one or both ovaries, with FSH level &gt; 20
             mIU/mL and estradiol ≤ 50 pg/mL

          -  Bothersome MS symptoms: Mean of two or more hot flashes/night sweats per 24 hrs; Hot
             flashes/night sweats rated as bothersome ('moderately' to 'a lot') and/or severe
             ('moderate' to 'severe') on 4 or more 12 hour (day/night) blocks of times

          -  In general good health (determined by medical history, blood pressure, and heart rate)

          -  No history of endometrial, ovarian, or breast cancer; No abnormal mammogram in the
             last 2 years; Absence of any current severe or unstable medical illness

        MS considerations:

          -  If using psychotropic medications: no change in the past 3 months

          -  If on DMT, no change in past 6 months Normal vitamin D levels (20-50 ng/mL)

        Exclusion Criteria:

          -  BMI &gt;35 kg/m2 as higher BMI may affect PK/PD

          -  Use of hormone therapy or hormonal contraceptives 2 months prior to enrollment

          -  Use of any prescribed therapy that is taken specifically for hot flashes in the past 1
             month.

          -  Use of any over-the-counter or herbal therapies that are taken specifically for hot
             flashes in the past 2 weeks.

          -  Use of selective estrogen receptor modulators (SERMs) or aromatase inhibitors during
             the 2 months before enrollment.

          -  Known hypersensitivity or contraindications to estrogen.

          -  Drug or alcohol abuse in the past 1 year

          -  Depression: moderate or severe (HAD score &gt; 8) Other psychiatric disease meeting
             DSM-IV criteria

          -  Lifetime diagnosis of psychosis or bipolar disorder.

          -  Pregnancy, intending pregnancy, or breast feeding

        History of any of the following, as determined by clinician review of the potential
        participant's medical history:

          -  Pre-breast cancer or high-risk breast cancer condition;

          -  Abnormal bleeding suggestive of endometrial pre-cancer;

          -  Endometrial hyperplasia;

          -  Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable or
             under medical management;

          -  Active or past history of venous or arterial thromboembolism

          -  History of gallstones IF gallbladder intact

          -  Known or suspected estrogen-dependent neoplasia

          -  History of coronary artery disease

          -  Hypersensitivity (angioedema, anaphylaxis) to estrogens, bazedoxifene, or any
             ingredients

          -  Known hepatic impairment or disease

          -  Thyroid dysfunction on thyroid medications

          -  Known hypoparathyroidism

          -  Blood test results indicating:

          -  Liver function tests: AST &gt;2.5 times upper limit of normal; ALT &gt;2.5 times upper limit
             of normal; total bilirubin 1.5 times upper limit of normal;

          -  Kidney test: creatinine &gt;1.5 mg/dL;

          -  Blood count: hematocrit &lt;30%;

          -  Hemoglobin &lt;8 g/dL.

          -  Current participation in another drug trial or intervention study.

          -  Inability or unwillingness to complete the study procedures.

        MS considerations:

          -  Clinical relapse within the last three months (to ensure disease stability)

          -  Steroid treatment in prior 1 month

          -  Evidence of other structural brain disease (e.g. prior stroke)

        MRI considerations:

          -  Metal implants

          -  Prior head trauma

          -  Claustrophobia requiring anxiolytic or sedation, or other contraindication to MRI.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riley M Bove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Clinical Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016 Jun;22(7):935-43. doi: 10.1177/1352458515606211. Epub 2015 Oct 7.</citation>
    <PMID>26447063</PMID>
  </reference>
  <reference>
    <citation>Bove R, Chitnis T, Houtchens M. Menopause in multiple sclerosis: therapeutic considerations. J Neurol. 2014 Jul;261(7):1257-68. doi: 10.1007/s00415-013-7131-8. Epub 2013 Oct 8. Review.</citation>
    <PMID>24101131</PMID>
  </reference>
  <reference>
    <citation>Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, Wicks P, De Jager PL. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015 Jan;4(1):18-24. doi: 10.1016/j.msard.2014.11.009. Epub 2014 Dec 9.</citation>
    <PMID>25787049</PMID>
  </reference>
  <reference>
    <citation>Bebo BF Jr, Dehghani B, Foster S, Kurniawan A, Lopez FJ, Sherman LS. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 2009 May;57(7):777-90. doi: 10.1002/glia.20805.</citation>
    <PMID>19031437</PMID>
  </reference>
  <reference>
    <citation>Boccardi M, Ghidoni R, Govoni S, Testa C, Benussi L, Bonetti M, Binetti G, Frisoni GB. Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. Menopause. 2006 Jul-Aug;13(4):584-91.</citation>
    <PMID>16837880</PMID>
  </reference>
  <reference>
    <citation>Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, De Jager PL. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014 Jan 21;82(3):222-9. doi: 10.1212/WNL.0000000000000033. Epub 2013 Dec 11.</citation>
    <PMID>24336141</PMID>
  </reference>
  <reference>
    <citation>North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012 Mar;19(3):257-71. doi: 10.1097/gme.0b013e31824b970a.</citation>
    <PMID>22367731</PMID>
  </reference>
  <reference>
    <citation>Pozzilli C, De Giglio L, Barletta VT, Marinelli F, Angelis FD, Gallo V, Pagano VA, Marini S, Piattella MC, Tomassini V, Pantano P. Oral contraceptives combined with interferon β in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015 Jun 18;2(4):e120. doi: 10.1212/NXI.0000000000000120. eCollection 2015 Aug.</citation>
    <PMID>26140279</PMID>
  </reference>
  <reference>
    <citation>Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.</citation>
    <PMID>26621682</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <results_first_submitted>April 24, 2020</results_first_submitted>
  <results_first_submitted_qc>June 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2020</results_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot flash</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02710214/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02710214/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duavee</title>
          <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duavee</title>
          <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="4.2"/>
                    <measurement group_id="B2" value="50.8" spread="2.9"/>
                    <measurement group_id="B3" value="51.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Modifying Therapy (DMT)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glatiramer Acetate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interferons</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Teriflunomide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fingolimod</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dimethyl Fumarate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocrelizumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Natalizumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale Score</title>
          <description>Scale of 0 to 10 (higher scores indicate greater disability).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" lower_limit="2.5" upper_limit="4.0"/>
                    <measurement group_id="B2" value="3.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="B3" value="3.0" lower_limit="2.5" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timed 25 Foot Walk</title>
          <population>N=16 with available data.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.91" spread="0.7"/>
                    <measurement group_id="B2" value="5.33" spread="1.6"/>
                    <measurement group_id="B3" value="5.15" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symbol Digit Modalities (SDMT) Raw Score</title>
          <description>The Symbol Digit Modalities Test (SDMT) is a screening instrument commonly used in clinical and research settings to assess cognitive dysfunction in MS. The final score is the correct number responses completed in 90 seconds and scores range between 0 and 110; higher scores indicate better performance.</description>
          <units>number of correct responses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="33" upper_limit="53"/>
                    <measurement group_id="B2" value="44" lower_limit="37" upper_limit="52"/>
                    <measurement group_id="B3" value="44" lower_limit="37" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDMT (z-score)</title>
          <description>Regression-based norms for the SDMT were used to convert participants' raw scores to demographically adjusted Z-scores, correcting for the effects of age, gender, and education. Scores are normalized so that 0 represents the mean, scores above 0 fall above the mean and are associated with greater performance on the SDMT. Scores below 0 fall below the mean and are associated with poorer performance on the SDMT</description>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.91" lower_limit="-1.65" upper_limit="0.19"/>
                    <measurement group_id="B2" value="-0.93" lower_limit="-1.76" upper_limit="0.07"/>
                    <measurement group_id="B3" value="-0.92" lower_limit="-1.66" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Letter Number Sequencing (LNS)</title>
          <description>The Letter Number Sequencing (LNS) is administered to asses working memory and processing speed. The score range is 0 to 21; higher scores indicate better performance on this test.</description>
          <units>number of correct responses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" lower_limit="10" upper_limit="12"/>
                    <measurement group_id="B2" value="9.5" lower_limit="8.5" upper_limit="11"/>
                    <measurement group_id="B3" value="10" lower_limit="9" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple Sclerosis Quality of Life 54 (MSQOL-54)</title>
          <description>Score range 0 to 100 for each sub-scale (mental, physical, energy); higher scores indicate better quality of life within that domain.</description>
          <population>N=20 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>MSQOL-54 Mental</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.3" lower_limit="72.6" upper_limit="82.3"/>
                    <measurement group_id="B2" value="71.5" lower_limit="49" upper_limit="86"/>
                    <measurement group_id="B3" value="74.2" lower_limit="67.5" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSQOL-54 Physical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" lower_limit="51.4" upper_limit="78.0"/>
                    <measurement group_id="B2" value="45.8" lower_limit="39.1" upper_limit="76.7"/>
                    <measurement group_id="B3" value="63.0" lower_limit="44.4" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSQOL-54 Energy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="24" upper_limit="76"/>
                    <measurement group_id="B2" value="40" lower_limit="12" upper_limit="52"/>
                    <measurement group_id="B3" value="38" lower_limit="20" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple Sclerosis Rating Scale Composite Score</title>
          <description>Score range of 0 to 32 (higher scores indicate worse patient reported disability).</description>
          <population>N=20 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="B2" value="11" lower_limit="5" upper_limit="16.5"/>
                    <measurement group_id="B3" value="8.5" lower_limit="3" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple Sclerosis Neuropsychological Questionnaire</title>
          <description>Score range 0 to 60 (scores &gt;27 indicate cognitive impairment).</description>
          <population>N=20 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="5" upper_limit="35"/>
                    <measurement group_id="B2" value="27" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="B3" value="19.5" lower_limit="11.5" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bladder Control Score</title>
          <description>Score range of 0 to 12 (higher scores indicate greater bladder dysfunction).</description>
          <population>N=20 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="B2" value="2" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="B3" value="1.5" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hot Flashes (per 24 hours)</title>
          <description>Median calculated from 2 weeks of daily hot flash diaries.</description>
          <population>N=19 with available data.</population>
          <units>hot flashes/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" lower_limit="2.2" upper_limit="8.9"/>
                    <measurement group_id="B2" value="3.4" lower_limit="1.6" upper_limit="8.6"/>
                    <measurement group_id="B3" value="4.1" lower_limit="1.8" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hot Flash Related Daily Interference Scale</title>
          <description>Score range 0 to 100 (higher scores indicate greater interference of hot flashes with daily life).</description>
          <population>N=16 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="7" upper_limit="26.5"/>
                    <measurement group_id="B2" value="27" lower_limit="15.5" upper_limit="66.5"/>
                    <measurement group_id="B3" value="23.5" lower_limit="9.5" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>Score range of 0 to 28 (0-7 indicates no clinically significant insomnia, 8-14 indicates sub-threshold insomnia, 15-21 indicates clinical insomnia of moderate severity, and 22-28 indicates severe clinical insomnia).</description>
          <population>N=9 with available data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" lower_limit="8.2" upper_limit="16.5"/>
                    <measurement group_id="B2" value="8" lower_limit="7.5" upper_limit="21"/>
                    <measurement group_id="B3" value="9" lower_limit="8" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hot Flash Related Daily Interference Scale (HFRDIS) Score</title>
        <description>The interference of vasomotor symptoms (VMS) with daily life will be assessed using the HFRDIS. Scores range from 0 to 100; higher scores indicate greater interference of hot flashes with daily life.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 21 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hot Flash Related Daily Interference Scale (HFRDIS) Score</title>
          <description>The interference of vasomotor symptoms (VMS) with daily life will be assessed using the HFRDIS. Scores range from 0 to 100; higher scores indicate greater interference of hot flashes with daily life.</description>
          <population>Data for this measure available only for 21 participants, due to missing data.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.5" upper_limit="14"/>
                    <measurement group_id="O2" value="9" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks</title>
        <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The number of women experiencing reduction in hot flashes at week 8 compared to baseline will be counted; when baseline data is unavailable 1-2 week on study data will be used.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 18 participants, due to missing data; in 3 cases, weeks 1-2 of on- study data was used when baseline was unavailable.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks</title>
          <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The number of women experiencing reduction in hot flashes at week 8 compared to baseline will be counted; when baseline data is unavailable 1-2 week on study data will be used.</description>
          <population>Data for this measure available only for 18 participants, due to missing data; in 3 cases, weeks 1-2 of on- study data was used when baseline was unavailable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Hot Flashes Per Day From Baseline to 8 Weeks</title>
        <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The average reduction in hot flashes per day over the course of the trial will be determined from the difference between 8 week and baseline frequency (by randomization group, treatment or placebo). When baseline data is not available, the 2 weeks on study data will be used as 'baseline'. Differences &lt;0 indicate reduction in hot flash frequency over the course of the trial.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 21 participants, due to missing data; in 3 cases, weeks 1-2 of on- study data was used when baseline was unavailable.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Hot Flashes Per Day From Baseline to 8 Weeks</title>
          <description>The number of daily vasomotor symptoms (VMS) will be collected in the form of hot flashes per 24 hours. The average hot flashes per day will be determined at 2 week intervals (baseline, 2 weeks, 4 weeks, and 8 weeks). The average reduction in hot flashes per day over the course of the trial will be determined from the difference between 8 week and baseline frequency (by randomization group, treatment or placebo). When baseline data is not available, the 2 weeks on study data will be used as 'baseline'. Differences &lt;0 indicate reduction in hot flash frequency over the course of the trial.</description>
          <population>Data for this measure available only for 21 participants, due to missing data; in 3 cases, weeks 1-2 of on- study data was used when baseline was unavailable.</population>
          <units>hot flashes/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-3.8" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-7.1" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Side Effects on the Treatment Satisfaction Questionnaire for Medication (TSQM)</title>
        <description>The primary measure will be the percentage of subjects reporting side effects (yes or no) on the Satisfaction Questionnaire for Medication (TSQM). The TSQM is used to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction.</description>
        <time_frame>8 weeks</time_frame>
        <population>Data for this measure available only for 16 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Side Effects on the Treatment Satisfaction Questionnaire for Medication (TSQM)</title>
          <description>The primary measure will be the percentage of subjects reporting side effects (yes or no) on the Satisfaction Questionnaire for Medication (TSQM). The TSQM is used to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction.</description>
          <population>Data for this measure available only for 16 participants, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Expanded Disability Status Scale (EDSS)</title>
        <description>EDSS total score is a metric used for quantifying disability in MS and monitoring changes in the level of disability over time. The EDSS will be assessed by a the trial neurologist at baseline and end of study (8 weeks). The score range is 0 to 10; higher scores indicate greater disability. All analyses were performed according to the intention-to-treat principle (primary) then the per-protocol principle.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 22 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Expanded Disability Status Scale (EDSS)</title>
          <description>EDSS total score is a metric used for quantifying disability in MS and monitoring changes in the level of disability over time. The EDSS will be assessed by a the trial neurologist at baseline and end of study (8 weeks). The score range is 0 to 10; higher scores indicate greater disability. All analyses were performed according to the intention-to-treat principle (primary) then the per-protocol principle.</description>
          <population>Data for this measure available only for 22 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.5" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the MS Quality of Life 54 (MSQOL-54)</title>
        <description>MS Quality of Life 54 (MSQOL-54) composite scores provide a patient reported quality of life score assessing physical QOL and mental QOL. A sub-scale of this assessment also assesses energy QOL. These will be measured at baseline and end of study (8 weeks). These scores fall within the range of 0 to 100; higher scores indicate better QOL within that domain or sub-scale.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 16 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the MS Quality of Life 54 (MSQOL-54)</title>
          <description>MS Quality of Life 54 (MSQOL-54) composite scores provide a patient reported quality of life score assessing physical QOL and mental QOL. A sub-scale of this assessment also assesses energy QOL. These will be measured at baseline and end of study (8 weeks). These scores fall within the range of 0 to 100; higher scores indicate better QOL within that domain or sub-scale.</description>
          <population>Data for this measure available only for 16 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MSQOL-54: Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="-2.2" upper_limit="9.8"/>
                    <measurement group_id="O2" value="0" lower_limit="-3.2" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSQOL-54: Mental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-2.8" upper_limit="3.8"/>
                    <measurement group_id="O2" value="0" lower_limit="-14.1" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSQOL-54: Energy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-6" upper_limit="6.5"/>
                    <measurement group_id="O2" value="0" lower_limit="-12" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Bladder Control Scale (BLCS)</title>
        <description>Bladder function will be assessed using the BLCS. Patient reported scores will be collected at baseline and at the end of study (8 weeks); scores fall within the range of 0 to 12. Higher scores indicate worse bladder function.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 16 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Bladder Control Scale (BLCS)</title>
          <description>Bladder function will be assessed using the BLCS. Patient reported scores will be collected at baseline and at the end of study (8 weeks); scores fall within the range of 0 to 12. Higher scores indicate worse bladder function.</description>
          <population>Data for this measure available only for 16 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Multiple Sclerosis Rating Scale (MSRS)</title>
        <description>Patient reported disability will be measured by the MSRS at baseline and end of study (8 weeks). Scores range of 0 to 32; higher scores indicate worse patient reported disability.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 16 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Multiple Sclerosis Rating Scale (MSRS)</title>
          <description>Patient reported disability will be measured by the MSRS at baseline and end of study (8 weeks). Scores range of 0 to 32; higher scores indicate worse patient reported disability.</description>
          <population>Data for this measure available only for 16 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-2.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)</title>
        <description>Cognitive function will be assessed by the MSNQ at baseline and end of study (8 weeks). Scores range 0 to 60 (scores &gt;27 indicate cognitive impairment).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 16 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)</title>
          <description>Cognitive function will be assessed by the MSNQ at baseline and end of study (8 weeks). Scores range 0 to 60 (scores &gt;27 indicate cognitive impairment).</description>
          <population>Data for this measure available only for 16 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-4" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Symbol Digit Modalities Test (SDMT) Raw Score</title>
        <description>SDMT is a screening instrument commonly used in clinical and research settings to assess cognitive dysfunction in MS. The SDMT will be administered at baseline and end of study (8 weeks). The final raw score is the correct number responses completed in 90 seconds and scores range between 0 and 110; higher scores indicate better performance.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 21 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Symbol Digit Modalities Test (SDMT) Raw Score</title>
          <description>SDMT is a screening instrument commonly used in clinical and research settings to assess cognitive dysfunction in MS. The SDMT will be administered at baseline and end of study (8 weeks). The final raw score is the correct number responses completed in 90 seconds and scores range between 0 and 110; higher scores indicate better performance.</description>
          <population>Data for this measure available only for 21 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="-3" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SDMT Z-score</title>
        <description>Regression-based norms for the SDMT were used to convert participants' raw scores at baseline and end of study (8 weeks) to demographically adjusted Z-scores, correcting for the effects of age, gender, and education. Scores are normalized so that 0 represents the mean, scores above 0 fall above the mean and are associated with greater performance on the SDMT. Scores below 0 fall below the mean and are associated with poorer performance on the SDMT.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>N=21 with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SDMT Z-score</title>
          <description>Regression-based norms for the SDMT were used to convert participants' raw scores at baseline and end of study (8 weeks) to demographically adjusted Z-scores, correcting for the effects of age, gender, and education. Scores are normalized so that 0 represents the mean, scores above 0 fall above the mean and are associated with greater performance on the SDMT. Scores below 0 fall below the mean and are associated with poorer performance on the SDMT.</description>
          <population>N=21 with available data.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="-0.18" upper_limit="1.01"/>
                    <measurement group_id="O2" value="0.13" lower_limit="-0.30" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Letter Number Sequencing (LNS) Performance</title>
        <description>The LNS is administered to asses working memory and processing speed at baseline and end of study (8 weeks). The score range is 0 to 21; higher scores indicate better performance on this test.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Data for this measure available only for 21 participants, due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Letter Number Sequencing (LNS) Performance</title>
          <description>The LNS is administered to asses working memory and processing speed at baseline and end of study (8 weeks). The score range is 0 to 21; higher scores indicate better performance on this test.</description>
          <population>Data for this measure available only for 21 participants, due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New or Enhancing Lesions on MRI</title>
        <description>To verify that CE+BZA does not yield any marked changes in inflammatory activity, a randomized subset of 12 participants will undergo MRI at baseline and end of study (8 weeks) to evaluate for new T2 lesions and new gadolinium enhancing lesions.</description>
        <time_frame>8 weeks</time_frame>
        <population>N=12 with MRI; participants were randomized to the MRI or no MRI group in this double blinded study; thus, by chance a higher number of women allocated to the Duavee arm received MRI's.</population>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New or Enhancing Lesions on MRI</title>
          <description>To verify that CE+BZA does not yield any marked changes in inflammatory activity, a randomized subset of 12 participants will undergo MRI at baseline and end of study (8 weeks) to evaluate for new T2 lesions and new gadolinium enhancing lesions.</description>
          <population>N=12 with MRI; participants were randomized to the MRI or no MRI group in this double blinded study; thus, by chance a higher number of women allocated to the Duavee arm received MRI's.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Missed Doses</title>
        <description>The number of missed doses will be assed at the end of study visit.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duavee</title>
            <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Missed Doses</title>
          <description>The number of missed doses will be assed at the end of study visit.</description>
          <units>missed doses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks, from start of study medication (at baseline visit) to end of study visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Duavee</title>
          <description>1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
Tissue Selective Estrogen Complex: Once-daily dosing of Duavee for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo pill daily for 8 weeks.
Placebo: Once-daily dosing of placebo for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Planned low sample size and our pre-specified power calculation allowed 80% power to observe a greater mean change in the treatment than in the control arm but did not provide sufficient power to assess statistical significance in this pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Riley Bove</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-595-2795</phone>
      <email>riley.bove@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

